At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Market Closed 12-12 16:00:00 EST
1.41
-0.11
-7.24%
盘后1.43
+0.02+1.42%
19:54 EST
High1.54Low1.41Vol1.21M
Open1.53D1 Closing1.52Amplitude8.55%
Mkt Cap99.69MTradable Cap80.70MTotal Shares70.70M
T/O1.77MT/O Rate2.11%Tradable Shares57.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025
Reuters  ·  12-10
Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters  ·  12-06
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Reuters  ·  12-05
BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
BUZZ-Biomea Fusion rises as diabetes drug shows promise
Reuters  ·  12-05
BUZZ-Biomea Fusion rises as diabetes drug shows promise
Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial
Reuters  ·  12-05
Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial
Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
THOMSON REUTERS  ·  12-05
Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares
Reuters  ·  12-05
Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares
Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares
Reuters  ·  12-03
Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares
Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC
Reuters  ·  12-02
Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
THOMSON REUTERS  ·  12-02
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan
Reuters  ·  12-02
Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  12-02
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion to Join Piper Sandler and Evercore Healthcare Investor Conferences
Reuters  ·  11-24
Biomea Fusion to Join Piper Sandler and Evercore Healthcare Investor Conferences
JPMorgan Downgrades Biomea Fusion to Underweight From Neutral
MT Newswires Live  ·  11-17
JPMorgan Downgrades Biomea Fusion to Underweight From Neutral
U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living
Reuters  ·  11-17
U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living
Biomea Fusion Inc : JP Morgan Cuts to Underweight From Neutral
THOMSON REUTERS  ·  11-17
Biomea Fusion Inc : JP Morgan Cuts to Underweight From Neutral
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
TIPRANKS  ·  11-15
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
Biomea Fusion Is Maintained at Buy by Citigroup
Dow Jones  ·  11-11
Biomea Fusion Is Maintained at Buy by Citigroup
Biomea Fusion Inc. to Present at Jefferies London Healthcare Conference
Reuters  ·  11-10
Biomea Fusion Inc. to Present at Jefferies London Healthcare Conference
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  11-05
Biomea Fusion Is Maintained at Buy by D. Boral Capital

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--